CC-122 HCl | Avadomide | CAS#1015474-32-4 | pleiotropic pathway modulator

MedKoo Cat#: 206921 | Name: Avadomide HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Avadomide, also known as CC-122, is an orally available pleiotropic pathway modulator with potential antineoplastic activity. CC-122 mimics an interferon response and has antitumor activity in DLBCL CC-122 binds Cereblon (CRBN) and promotes degradation of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo, and in patients, resulting in both cell autonomous as well as immunostimulatory effects.

Chemical Structure

Avadomide HCl

CAS#1398053-45-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 206921

Name: Avadomide HCl

CAS#: 1398053-45-6 (HCl)

Chemical Formula: C14H15ClN4O3

Exact Mass: 0.0000

Molecular Weight: 322.75

Elemental Analysis: C, 52.10; H, 4.68; Cl, 10.98; N, 17.36; O, 14.87

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,950.00	2 Weeks
2g	USD 6,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1398053-45-6 (HCl) 1015474-32-4 (free base)

Synonym

CC 122 HCl; CC-122; CC122, Avadomide HCl; Avadomide hydrochloride

IUPAC/Chemical Name

3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride

InChi Key

BVJRNKXVSYLNFD-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H14N4O3.ClH/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20;/h2-4,10H,5-6,15H2,1H3,(H,17,19,20);1H

SMILES Code

O=C(C(N1C(C)=NC2=C(C(N)=CC=C2)C1=O)CC3)NC3=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 322.75 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tsang M, Cleveland J, Rubenstein JL. On point in primary CNS lymphoma. Hematol Oncol. 2020 Dec;38(5):640-647. doi: 10.1002/hon.2761. Epub 2020 Jul 3. PMID: 32510610; PMCID: PMC8815361. 2: Renneville A, Gasser JA, Grinshpun DE, Jean Beltran PM, Udeshi ND, Matyskiela ME, Clayton T, McConkey M, Viswanathan K, Tepper A, Guirguis AA, Sellar RS, Cotteret S, Marzac C, Saada V, De Botton S, Kiladjian JJ, Cayuela JM, Rolfe M, Chamberlain PP, Carr SA, Ebert BL. Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies. Blood Cancer Discov. 2021 May;2(3):250-265. doi: 10.1158/2643-3230.BCD-20-0105. Epub 2021 Mar 10. PMID: 34027417; PMCID: PMC8133393. 3: Fuchs O. Targeting cereblon in hematologic malignancies. Blood Rev. 2023 Jan;57:100994. doi: 10.1016/j.blre.2022.100994. Epub 2022 Jul 31. PMID: 35933246. 4: Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020 Mar 26;135(13):996-1007. doi: 10.1182/blood.2019002395. Erratum in: Blood. 2021 Apr 15;137(15):2126. PMID: 31977002; PMCID: PMC7099331. 5: Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, Shen F, Hagner P, Li Y, Dobmeyer J, Gong N, Uttamsingh S, Pourdehnad M, Ribrag V. Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. EJHaem. 2022 Feb 14;3(2):394-405. doi: 10.1002/jha2.394. PMID: 35846031; PMCID: PMC9175947. 6: Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, Chen T, Klein C, Hagner PR, Nikolova Z, Ribrag V. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non- Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematol. 2020 Sep;7(9):e649-e659. doi: 10.1016/S2352-3026(20)30208-8. Epub 2020 Aug 3. PMID: 32758434. 7: Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV. Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies. AAPS J. 2021 Aug 27;23(5):103. doi: 10.1208/s12248-021-00623-8. Erratum in: AAPS J. 2022 Jan 14;24(1):29. PMID: 34453265; PMCID: PMC8397660. 8: Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones J, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood. 2021 Jan 14;137(2):216-231. doi: 10.1182/blood.2020006073. PMID: 33024998; PMCID: PMC7820876. 9: Rasco DW, Papadopoulos KP, Pourdehnad M, Gandhi AK, Hagner PR, Li Y, Wei X, Chopra R, Hege K, DiMartino J, Shih K. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin Cancer Res. 2019 Jan 1;25(1):90-98. doi: 10.1158/1078-0432.CCR-18-1203. Epub 2018 Sep 10. PMID: 30201761. 10: Hatake K, Chou T, Doi T, Terui Y, Kato H, Hirose T, Seo S, Pourdehnad M, Ogaki Y, Fujimoto H, Hagner PR, Yamamoto K. Phase I, multicenter, dose- escalation study of avadomide in adult Japanese patients with advanced malignancies. Cancer Sci. 2021 Jan;112(1):331-338. doi: 10.1111/cas.14704. Epub 2020 Nov 26. PMID: 33075165; PMCID: PMC7780008. 11: Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S, Haeske H, Hege K, Pourdehnad M, Kuruvilla J. Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. EJHaem. 2022 Jan 14;3(1):139-153. doi: 10.1002/jha2.375. PMID: 35846221; PMCID: PMC9176062. 12: Heim C, Hartmann MD. High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system. Acta Crystallogr D Struct Biol. 2022 Mar 1;78(Pt 3):290-298. doi: 10.1107/S2059798322000092. Epub 2022 Feb 18. PMID: 35234143; PMCID: PMC8900816. 13: Abbiati RA, Pourdehnad M, Carrancio S, Pierce DW, Kasibhatla S, McConnell M, Trotter MWB, Loos R, Santini CC, Ratushny AV. Correction to: Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies. AAPS J. 2022 Jan 14;24(1):29. doi: 10.1208/s12248-021-00673-y. Erratum for: AAPS J. 2021 Aug 27;23(5):103. PMID: 35038051; PMCID: PMC9172776. 14: Ogasawara K, MacGorman K, Liu L, Chen J, Carayannopoulos LN, Zhou S, Palmisano M, Li Y. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects. J Clin Pharmacol. 2019 Dec;59(12):1620-1631. doi: 10.1002/jcph.1453. Epub 2019 Jun 6. PMID: 31172535; PMCID: PMC6851786. 15: Li Y, MacGorman K, Liu L, Chen J, Hoffmann M, Palmisano M, Zhou S. Single- Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment. Clin Pharmacol Drug Dev. 2020 Oct;9(7):785-796. doi: 10.1002/cpdd.760. Epub 2019 Dec 31. PMID: 31891240. 16: Carpio C, Bouabdallah R, Ysebaert L, et al. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood. 2020;135(13):996-1007. Blood. 2021 Apr 15;137(15):2126. doi: 10.1182/blood.2021011546. Erratum for: Blood. 2020 Mar 26;135(13):996-1007. PMID: 33856449; PMCID: PMC8057265. 17: Yamshon S, Ruan J. IMiDs New and Old. Curr Hematol Malig Rep. 2019 Oct;14(5):414-425. doi: 10.1007/s11899-019-00536-6. PMID: 31302872. 18: Ito T, Handa H. [Cereblon as a primary target of IMiDs]. Rinsho Ketsueki. 2019;60(9):1013-1019. Japanese. doi: 10.11406/rinketsu.60.1013. PMID: 31597822. 19: Hagner PR, Chiu H, Chopra VS, Colombo M, Patel N, Estevez MO, Waldman MF, Loos R, Towfic F, Gandhi AK. Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL. Clin Cancer Res. 2022 Aug 2;28(15):3367-3377. doi: 10.1158/1078-0432.CCR-21-3347. PMID: 35583604; PMCID: PMC9662945. 20: Ioannou N, Jain K, Ramsay AG. Immunomodulatory Drugs for the Treatment of B Cell Malignancies. Int J Mol Sci. 2021 Aug 9;22(16):8572. doi: 10.3390/ijms22168572. PMID: 34445275; PMCID: PMC8395307. 9: Cubillos-Zapata C, Córdoba R, Avendaño-Ortiz J, Lopez-Collazo E. Thalidomide analog CC-122 induces a refractory state in monocytes from patients with diffuse large B cell lymphoma. Leuk Lymphoma. 2017 Aug;58(8):1999-2001. doi: 10.1080/10428194.2016.1272686. Epub 2017 Jan 16. Retraction in: Leuk Lymphoma. 2017 Aug;58(8):I. PubMed PMID: 28093007.